These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29543500)

  • 21. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.
    Winkler ML; Papp-Wallace KM; Hujer AM; Domitrovic TN; Hujer KM; Hurless KN; Tuohy M; Hall G; Bonomo RA
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1020-9. PubMed ID: 25451057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fosfomycin.
    Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
    Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem.
    Perdigão Neto LV; Oliveira MS; Martins RCR; Marchi AP; Gaudereto JJ; da Costa LATJ; de Lima LFA; Takeda CFV; Costa SF; Levin AS
    J Antimicrob Chemother; 2019 Jan; 74(1):177-181. PubMed ID: 30376073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colistin: still a lifesaver for the 21st century?
    Karaiskos I; Souli M; Galani I; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil.
    Rossi F; Cury AP; Franco MRG; Testa R; Nichols WW
    Braz J Infect Dis; 2017; 21(5):569-573. PubMed ID: 28435011
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I; Giamarellou H
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG; Bradford PA; Newell P; Wardman A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
    Onorato L; Di Caprio G; Signoriello S; Coppola N
    Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's new in the treatment of multidrug-resistant gram-negative infections?
    Mo Y; Lorenzo M; Farghaly S; Kaur K; Housman ST
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):171-181. PubMed ID: 30224228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli.
    Domalaon R; De Silva PM; Kumar A; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of SuperCAZ/AVI® Medium for Screening Ceftazidime-avibactam Resistant Gram-negative Isolates.
    Sadek M; Poirel L; Dominguez Pino M; D'Emidio F; Pomponio S; Nordmann P
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115475. PubMed ID: 34419742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
    Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.